These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38735015)

  • 1. Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: a Swedish national population-based register study.
    Linder M; Ekbom A; Brobert G; Vogtländer K; Balabanova Y; Becattini C; Carrier M; Cohen AT; Coleman CI; Khorana AA; Lee AYY; Psaroudakis G; Abdelgawwad K; Rivera M; Schaefer B; Giunta DH
    J Thromb Thrombolysis; 2024 Aug; 57(6):973-983. PubMed ID: 38735015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer.
    Lee JH; Oh YM; Lee SD; Lee JS
    J Korean Med Sci; 2019 Jun; 34(21):e160. PubMed ID: 31144482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US Program.
    Caroti KS; Khorana AA; Becattini C; Lee AYY; Ekbom A; Carrier M; Cohen AT; Brescia C; Abdelgawwad K; Psaroudakis G; Rivera M; Schaefer B; Brobert G; Coleman CI
    Clin Appl Thromb Hemost; 2023; 29():10760296231189282. PubMed ID: 37583314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.
    Perrotta C; Chahla J; Badariotti G; Ramos J
    Cochrane Database Syst Rev; 2020 May; 5(5):CD005259. PubMed ID: 32374919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
    Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
    JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
    Rutjes AW; Porreca E; Candeloro M; Valeriani E; Di Nisio M
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD008500. PubMed ID: 33337539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
    Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and Safety of Extended Treatment Apixaban Versus Low-Molecular-Weight Heparin in Cancer-Associated Venous Thromboembolism.
    Cohen AT; Dhamane AD; Liu X; Singh R; Han S; Stellhorn R; Wang J; Luo X
    J Natl Compr Canc Netw; 2024 Aug; 22(6):397-403. PubMed ID: 39151451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism.
    Costa OS; Kohn CG; Kuderer NM; Lyman GH; Bunz TJ; Coleman CI
    Blood Adv; 2020 Sep; 4(17):4045-4051. PubMed ID: 32853381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study.
    Woodruff S; Lee AYY; Carrier M; Feugère G; Abreu P; Heissler J
    J Thromb Thrombolysis; 2019 May; 47(4):495-504. PubMed ID: 30859370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer.
    Van Matre ET; Reynolds PM; MacLaren R; Mueller SW; Wright GC; Moss M; Burnham EL; Ho PM; Vandivier RW; Kiser TH
    J Thromb Haemost; 2018 Dec; 16(12):2492-2500. PubMed ID: 30347498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer.
    Streiff MB; Milentijevic D; McCrae K; Yannicelli D; Fortier J; Nelson WW; Laliberté F; Crivera C; Lefebvre P; Schein J; Khorana AA
    Am J Hematol; 2018 May; 93(5):664-671. PubMed ID: 29396864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study.
    Stepien K; Nowak K; Zalewski J; Pac A; Undas A
    Vascul Pharmacol; 2019 Sep; 120():106567. PubMed ID: 31158568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists.
    Eerenberg ES; Middeldorp S; Levi M; Lensing AW; Büller HR
    J Thromb Haemost; 2015 Sep; 13(9):1590-6. PubMed ID: 26179293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.
    Perrotta C; Chahla J; Badariotti G; Ramos J
    Cochrane Database Syst Rev; 2022 Aug; 8(8):CD005259. PubMed ID: 35993965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent thromboembolism, bleeding, and mortality in Asian patients with venous thromboembolism receiving different oral anticoagulants: A nationwide analysis.
    Lee MC; Liao CT; Feng IJ; Yu T; Chang WT; Shih MF; Su HC; Toh HS
    Medicine (Baltimore); 2022 Sep; 101(37):e30412. PubMed ID: 36123930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the Efficacy and Safety of Rivaroxaban and Low Molecular Heparin in Preventing Venous Thromboembolism in Inpatient Cancer Patients.
    Wu S; Guan C; Chang S; Wang C; Zhang J
    Ann Pharmacother; 2024 Mar; 58(3):214-222. PubMed ID: 37312538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
    Andras A; Sala Tenna A; Stewart M
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD002001. PubMed ID: 28737834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
    Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
    J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.